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Abstract
Background: After traumatic brain injury (TBI), brain tissue can be further damaged when cerebral autoregulation is
impaired. Managing cerebral perfusion pressure (CPP) according to computed “optimal CPP” values based on
cerebrovascular reactivity indices might contribute to preventing such secondary injuries. In this study, we
examined the discriminative value of a low-resolution long pressure reactivity index (LPRx) and its derived “optimal
CPP” in comparison to the well-established high-resolution pressure reactivity index (PRx).
Methods: Using the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-
TBI) study dataset, the association of LPRx (correlation between 1-min averages of intracranial pressure and arterial
blood pressure over a moving time frame of 20 min) and PRx (correlation between 10-s averages of intracranial
pressure and arterial blood pressure over a moving time frame of 5 min) to outcome was assessed and compared
using univariate and multivariate regression analysis. “Optimal CPP” values were calculated using a multi-window
algorithm that was based on either LPRx or PRx, and their discriminative ability was compared.
Results: LPRx and PRx were both significant predictors of mortality in univariate and multivariate regression
analysis, but PRx displayed a higher discriminative ability. Similarly, deviations of actual CPP from “optimal CPP”
values calculated from each index were significantly associated with outcome in univariate and multivariate analysis.
“Optimal CPP” based on PRx, however, trended towards more precise predictions.
Conclusions: LPRx and its derived “optimal CPP” which are based on low-resolution data were significantly
associated with outcome after TBI. However, they did not reach the discriminative ability of the high-resolution PRx
and its derived “optimal CPP.” Nevertheless, LPRx might still be an interesting tool to assess cerebrovascular
reactivity in centers without high-resolution signal monitoring.
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Background
Following severe traumatic brain injury (TBI), secondary
injury cascades occur that affect cerebral blood flow
(CBF). They may lead to ischemia when the cerebral
perfusion pressure (CPP), the pressure gradient for cere-
bral blood flow defined as arterial blood pressure (ABP)
minus intracranial pressure (ICP), is too low or to
hyperemia and increased ICP when the CPP is too high
[1–3]. The brain is vulnerable to changes in CPP after
severe TBI because cerebral autoregulation, which nor-
mally maintains constant CBF during changes in ABP, is
often impaired in those patients [1, 3–5]. A mainstay in
the clinical management of TBI is therefore the avoid-
ance of secondary brain injury by controlling ICP and
ensuring adequate, non-harmful CBF by regulating CPP.
Current guidelines (2016) by the Brain Trauma Founda-
tion recommend keeping CPP between 60 and 70mmHg
[6]. However, likely due to the heterogeneity of cerebral
injuries in patients with TBI, a CPP-oriented therapy
with one fixed target for all patients failed to demon-
strate improved neurological outcome compared to ICP-
targeted therapy in a large randomized-controlled trial
[7]. This is why a patient-customized approach has been
proposed which uses the pressure reactivity index (PRx)
to determine the optimal CPP (CPPopt) in an individual
patient. The PRx, calculated as a moving correlation co-
efficient between slow waves of ABP and ICP, is a surro-
gate marker for cerebral autoregulation and has been
associated with outcome after TBI in multiple studies
[8–12]. Positive PRx values indicate dysfunctional cere-
brovascular reactivity and are associated with increased
mortality and unfavorable outcome, while negative
values indicate intact pressure reactivity [9]. Using
computational methods, this relationship can be
exploited to determine an optimal CPP that corresponds
to the lowest, most favorable PRx values in a patient [12,
13]. As the PRx and thus CPPopt are derived from ABP
and ICP signals that are continuously monitored, the
CPPopt recommendation can be constantly updated and
refined, thereby providing the possibility to customize
the clinical management also over the course of time in
an individual patient. The automated CPPopt algorithm
introduced by Aries et al. which uses a single, 4-h
moving monitoring window to calculate CPPopt has
been developed further to a multi-window algorithm.
Deviations of CPP from CPPopt have been shown to
correlate with clinical outcome in several retrospective
studies [13–15], and the first prospective study assessing
the feasibility of clinical management based on continu-
ous determination of CPPopt is currently ongoing
(COGiTATE trial) [16]. However, as the PRx and thus
PRx-based CPPopt calculations require continuous, full-
resolution waveforms of ABP and ICP, the CPPopt con-
cept is currently limited to specialized neurocritical care
units. In an attempt to increase accessibility of the PRx
concept, a similarly calculated PRx variant called the
long pressure reactivity index (LPRx) has been intro-
duced which can be derived from lower resolution,
minute-by-minute resampled ICP and ABP signals that
standard monitoring devices in most intensive care units
(ICU) can provide [17]. However, it remains unclear
whether minute-by-minute monitoring might be of high
enough resolution to evaluate autoregulation in patients
with TBI and derive clinically relevant information from
it. In fact, previous studies have yielded mixed results
and drawn different conclusions [8, 17–19].
In light of these previous results, we assessed the
discriminative value of LPRx and PRx and the perform-
ance of the most recent, multi-window CPPopt algo-
rithm currently used in the COGiTATE trial but built
on the LPRx instead of the PRx.
Methods
Patient cohort
For this study, all patients from the high-resolution (HR)
ICU cohort of the Collaborative European NeuroTrauma
Effectiveness Research in TBI (CENTER-TBI) study (EC
grant 602150), prospectively recruited between January
2015 and December 2017 at 21 centers in the European
Union (EU), were screened and included if they met the
following inclusion criteria: (a) availability of high-
frequency ICU monitoring data (i.e., continuous ABP
and ICP monitoring), (b) availability of Glasgow Out-
come Scale Extended (GOSE) at 6 months, (c) age of 18
years or older, and (d) ICP was measured via intrapar-
enchymal probe. During the analysis, 8 patients were
excluded from our study because PRx- or LPRx-based
CPPopt could not be calculated due to either too short
or interrupted monitoring data after artifact removal (3
patients) or very high mean ICP values over the entire
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monitoring period exceeding 55mmHg and resulting in
persistent PRx values close to + 1, making the CPPopt
calculation meaningless (5 patients). For all remaining
patients, the following demographic data was retrieved
from the CENTER-TBI Neurobot database (version 2.0,
CENTER core): age, sex, Glasgow Coma Scale (GCS),
GCS–motor component, pupillary response at admission
(bilaterally reactive, unilaterally reactive, bilaterally unre-
active), and necessity of decompressive surgery (yes/no).
For assessment of outcome, the imputed 6-month GOSE
variable was used which includes both observed ratings
and imputed values. For comparative analyses, patients
were dichotomized into fatal vs. non-fatal outcome and
unfavorable (GOSE 1–4) vs. favorable (GOSE 5–8)
outcome.
ICU monitoring data: recording and processing
High-frequency digital signals from continuous ABP and
ICP monitoring during intensive care treatment were re-
corded for all patients included in this study. Recording
was intended to start within 24 h of injury and encom-
passed the entire time that ICP/ABP monitoring was
clinically required. ABP was monitored through radial or
femoral arterial lines while ICP was monitored through
intraparenchymal ICP probes, parenchymal fiber optic
pressure sensors, or external ventricular drains. Signals
were either digitally recorded or digitalized via an A/D
converter (DT9801; Data Translation, USA MA), hereby
sampled at frequency of 100 Hz or higher, using the
ICM+ software (Cambridge Enterprise Ltd., UK), a
Moberg CNS Monitor (Moberg Research Inc., USA), or
a combination of both. Signal artifacts were removed
manually and using automated algorithms. Data process-
ing of all monitored signals was conducted using ICM+.
Moving averages of 10 s (updated every 10 s) were calcu-
lated for ABP, ICP, and CPP (= ABP − ICP). PRx was
calculated as a moving Pearson correlation coefficient
between 10 s averaged ICP and ABP values in a moving
time window of 5 min. For the LPRx, 1-min averages of
ICP and ABP were correlated within a moving time win-
dow of 20 min. PRx, LPRx, and minute-by-minute aver-
ages of ABP and ICP were updated every minute.
CPPopt was calculated using a multi-window, weighted
approach. Details on the exact ICM+ settings and calcu-
lation methods can be found in the COGiTATE protocol
paper by Beqiri et al. [16]. In short, a 5-min median CPP
time trend was calculated along the PRx (Fisher trans-
formed to achieve normal distribution) and these PRx
values were grouped into CPP bins of 5 mmHg (within
40–120 mmHg range). The CPP value corresponding to
the lowest associated PRx value was determined using
an automatic parabolic curve fitting method. For each
time point, this method was conducted for 36 different
preceding time windows ranging from 2 to 8 h (with 10-
min increasing steps) in length, resulting in 36 PRx-CPP
plots. Following certain inclusion criteria (e.g., rejecting
non-physiological values), those 36 different CPPopt
values were combined according to particular heuristic
weighting rules, which included higher weights given to
more recent time windows and rejection of non-
parabolic curves, to contribute to the final CPPopt.
CPPoptLPRx was calculated accordingly, however using
the LPRx instead of PRx. CPPoptPRx and CPPoptLPRx
were updated every minute. The difference between me-
dian CPP and each computed CPPoptPRx/CPPoptLPRx
value was continuously calculated for every minute of
the recording period (ΔCPPoptLPRx, ΔCPPoptLPRx). The
yield of CPPoptPRx/CPPoptLPRx was defined and calcu-
lated as the count of CPPopt values divided by the count
of CPP values across the whole recording period. Values
of all monitoring parameters (ABP, ICP, PRx, LPRx,
CPPoptPRx, CPPoptLPRx, ΔCPPoptPRx, ΔCPPoptLPRx)
were at last averaged over the entire monitoring period
for each patient.
Statistical analysis
Demographical variables and ICU monitoring parame-
ters were descriptively analyzed and compared between
dichotomized outcome groups using the Mann-Whitney
U test for continuous variables and the chi-squared test
for categorical variables. Results are given as median +
interquartile range (IQR), unless stated otherwise. Spear-
man’s rank correlation coefficient was used to evaluate
correlation between PRx and LPRx while a Bland-
Altman plot was used to assess agreement between both
indices. Univariate logistic regression in regard to di-
chotomized outcomes was applied with either LPRx or
PRx as predictors. Discrimination was assessed via area
under the receiver operating curve (AUC) and compared
using DeLong’s test. Multivariate logistic regression was
conducted to assess the association between either LPRx
or PRx and dichotomized outcomes with adjustment for
the IMPACT core variables age, admission GCS motor
score (GCS-Motor), and pupil reactivity status (bilat-
erally reactive, unilateral reactive, bilateral unreactive)
[20]. The goodness-of-fit of the full model (IMPACT
core variables + LPRx or PRx) was tested against the
IMPACT-only model via a likelihood-ratio test, and
AUCs were calculated for each model. In all statistical
tests, the level of significance was set at 0.05, and no p
value adjustment for multiple testing was applied due to
the exploratory nature of this study. All statistical ana-
lyses were performed in the R environment [21].
Results
Patient demographics
A total of 224 patients (176 males and 48 females) ran-
ging in age from 18 to 85 years with a median age of 51
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(IQR, 33–64 years) were included in this study. Patient
demographics and mean values of ICU monitoring pa-
rameters are provided in Table 1. The median GCS
score at admission was 6 (IQR, 3–10) with a range from
3 to 15. Decompressive craniectomy was performed in
47 patients during their hospital stay. Six months after
admission, 52 patients were dead yielding a mortality
rate of 23%. The outcome of 135 patients (60%) was
considered unfavorable (i.e., GOSE 1–4) at 6 months
post-injury.
PRx and LPRx
Results from Spearman’s test showed that there was a
significantly positive, albeit only moderate correlation
between mean LPRx and PRx values in our patient co-
hort (r = 0.63, p < 0.001; Fig. 1a). This correlation was
slightly higher for the subgroup of patients with severe
TBI (r = 0.68, p < 0.001). A Bland-Altman plot for agree-
ment between LPRx and PRx yielded a mean bias of
0.076 with 95% limits of agreement at − 0.210 and +
0.362 (Fig. 1b). There was a clear association of higher
mortality rates with higher mean LPRx and PRx values,
as shown in Fig. 2. Accordingly, both LPRx and PRx
were significantly higher in patients with fatal outcome
compared to surviving patients (LPRx, 0.025 (− 0.096–
0.212) vs. − 0.064 (− 0.175–0.054), p < 0.001; PRx, 0.163
(0.016–0.314) vs. 0.009 (− 0.082–0.112), p < 0.001).
When dichotomizing patients into unfavorable vs. favor-
able outcome, a significant group difference could only
be detected for the PRx but not for the LPRx (PRx,
0.052 (− 0.067–0.195) vs. − 0.014 (− 0.086–0.098), p =
0.013; LPRx, − 0.026 (− 0.142–0.105) vs. − 0.063 (−
0.148–0.051), p = 0.204). In univariate regression
analysis, both PRx and LPRx were significantly associ-
ated with mortality (Table 2 (A)), which generally in-
creased with higher index values. Discriminative ability
was higher for the PRx (AUC 0.70 (0.61–0.79), p < 0.001)
compared to the LPRx (AUC 0.66 (0.58–0.75), p <
0.001), although this difference did not reach signifi-
cance in this patient cohort (DeLong’s test, p = 0.348;
Fig. 3a). Interestingly, discriminative ability of both re-
activity indices seemed to be particularly strong for the
subgroup of patients with severe TBI (LPRx: AUC 0.69
(0.57–0.81) and PRx: AUC 0.73 (0.62–0.84)). The dis-
criminative value in regard to unfavorable outcome was
considerably worse for both indices, and only the PRx
reached significance in univariate regression with an
AUC of 0.60 (0.52–0.67, p = 0.007). However, in com-
parison to the AUC of LPRx (0.55 (0.47–0.63, p =
0.102)), no significant difference could be observed via
DeLong’s test either (p = 0.167).
Similar results were obtained when examining the pre-
dictive value of the reactivity indices in relation to pa-
tient outcome over the post-traumatic temporal course
(Fig. 4a, b). Discrimination tended to be higher for PRx
compared to LPRx for both mortality and, with excep-
tions at days 4 and 5, unfavorable outcome. However,
those differences did not reach significance at any ob-
served time point.
When adjusted for age, GCS-Motor, and pupillary re-
sponse (IMPACT core variables) in multivariate regres-
sion analysis, both LPRx and PRx remained independent
predictors for mortality (Table 2 (A)). In regard to un-
favorable outcome, neither of the indices was found to
be a significant predictor in the same multivariate model
(PRx: p = 0.120 and LPRx: p = 0.976). Importantly, when
also controlling for ICP and CPP in the multivariate
model, only PRx but not LPRx remained significant
(Table 2 (C)). Nevertheless, adding either LPRx or PRx
to the IMPACT core model led to a notable increase of
the AUC for prediction of mortality: 0.78 (0.70–0.85)
when adding LPRx and 0.80 (0.72–0.88) when adding
PRx, compared to 0.74 (0.66–0.82) for the model with-
out indices (Fig. 3b). For both LPRx and PRx, the
goodness-of-fit of the combined IMPACT + index
model was significantly improved when compared to the
mere IMPACT model as assessed by likelihood-ratio
tests (χ2 = 6.79, p = 0.009 (LPRx), and χ2 = 15.13, p <
0.001 (PRx), respectively). Results and trends in our
Table 1 Patient demographics
All patients
Number of patients 224
Age (years) 51 (33–64)
Sex
- Female (%) 48 (21%)
- Male (%) 176 (79%)
GCS total 6 (3–10)
GCS motor 4 (1–5)
Pupillary response
- Both reactive 150 (67%)
- One reactive 17 (8%)
- Both unreactive 39 (17%)
- Unknown 18 (8%)
ABP (mmHg) 83.6 (78.8–90.0)
ICP (mmHg) 12.6 (9.6–16.1)
CPP (mmHg) 71.6 (65.2–77.4)
PRx 0.027 (− 0.074–0.162)
LPRx − 0.049 (− 0.145–0.079)
GOSE 3 (3–5)
Unfavorable outcome (%) 135 (60%)
Fatal outcome (%) 51 (23%)
ABP arterial blood pressure, CPP cerebral perfusion pressure, GCS Glasgow
Coma Scale, GOSE Glasgow Outcome Scale Extended, ICP intracranial pressure,
LPRx long pressure reactivity index, PRx pressure reactivity index
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analysis were similar when patients with decompressive
surgery were excluded (data not shown).
Optimal cerebral perfusion pressure
Both the LPRx-based and the PRx-based CPPopt calcu-
lations produced a similar median CPPopt value in our
patient cohort (71.4 (65.9–76.6) mmHg vs. 72.0 (65.9–
77.5) mmHg, p = 0.445). Correspondingly, we found no
significant difference in CPPopt yield between the LPRx-
and PRx-based calculations (80.0 (70.4-86.7) % vs. 80.4
(71.4–87.6) %, p = 0.625). The difference between CPP
and CPPoptPRx (ΔCPPoptPRx) was significantly higher in
patients with fatal outcome compared to survivors (3.7
(1.9–5.8) mmHg vs. 1.9 (0.9–4.1) mmHg, p = 0.003).
This relation was also apparent when examining the
ΔCPPoptLPRx, although it was considerably lower (2.3
(1.0–3.6) mmHg vs. 1.5 (0.7–2.9), p = 0.049).
ΔCPPoptLPRx and ΔCPPoptPRx were significant predic-
tors of mortality both in univariate and multivariate
analyses with age, GCS-Motor, and pupillary as covari-
ates, underlining the association between both CPPopt
versions and clinical outcome (Table 2 (B)). However,
when also including ICP and CPP in the multivariate
model, only ΔCPPoptPRx remained a significant
predictor (Table 2 (D)). Still, there was no significant
difference between the AUCs of ΔCPPoptLPRx and
ΔCPPoptPRx when predicting mortality (0.67 (0.59–0.76)
ΔCPPoptLPRx vs. 0.71 (0.62–0.79) ΔCPPoptPRx; p = 0.237;
Fig. 3c). Assessment of the discriminative value of both
ΔCPPopt variables over the post-traumatic course did
reveal neither a clear increase/decrease over time nor a
clear superiority of one ΔCPPopt variable over the other.
Fig. 1 a Spearman’s correlation between LPRx and PRx. b Bland-Altman plot for agreement between PRx and LPRx showing mean bias (solid
line), zero difference (thin dashed line), and 95% lines of agreement (thick dashed lines)
Fig. 2 Histograms showing the absolute (a, b) and relative (c, d) proportion of patients with fatal outcome for different LPRx and PRx values
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However, a significant statistical difference could be ob-
served at day 6, with ΔCPPoptPRx displaying a significant
higher AUC compared to ΔCPPoptLPRx when predicting
death (p = 0.007, DeLong’s test; Fig. 4c, d). Similar to our
findings with the LPRx and PRx, the goodness-of-fit was
significantly improved when adding either ΔCPPoptLPRx
or ΔCPPoptPRx to the basic IMPACT model (χ
2 = 9.39,
p = 0.002 (IMPACT + ΔCPPoptLPRx), and χ
2 = 16.71, p <
0.001 (IMPACT + ΔCPPoptPRx); Fig. 3d). The LPRx plus
IMPACT model displayed an AUC of 0.77 (0.69–0.85),
and the PRx plus IMPACT model an AUC of 0.80
(0.72–0.87). Similar to our previous findings with the
PRx and LPRx, equivalent results were obtained for all
CPPopt-associated analyses without including surgically
decompressed patients, except for results from the
multivariate models including ICP and CPP where
ΔCPPoptLPRx remained a significant predictor when only
including patients without decompressive craniectomy
(data not shown).
Cerebral perfusion pressure targeted therapy
Because a difference of ± 5 mmHg between the actual
CPP and calculated CPPopt has been proposed as an ac-
ceptable range for CPP-targeted therapy [12, 16], we
Table 2 Results from univariate and multivariate logistic regression analysis in regard to mortality for LPRx, PRx, ΔLPRx-CPPopt, and
ΔPRx-CPPopt
A Parameter Index: LPRx Index: PRx
Coefficient p value Coefficient p value
Univariate Index 3.484 < 0.001 4.244 < 0.001
Multivariate Age 0.039 0.001 0.036 0.003
GCS-Motor − 0.191 0.068 − 0.202 0.059
Pupillary response 0.304 0.197 0.333 0.173
Index 2.634 0.011 3.868 < 0.001
B Parameter ΔCPPopt: LPRx ΔCPPopt: PRx
Coefficient p value Coefficient p value
Univariate ΔCPPopt − 0.122 0.003 − 0.148 < 0.001
Multivariate Age 0.049 < 0.001 0.050 < 0.001
GCS-Motor − 0.196 0.059 − 0.227 0.034
Pupillary response 0.308 0.198 0.257 0.296
ΔCPPopt − 0.139 0.003 − 0.159 < 0.001
C Parameter Index: LPRx Index: PRx
Coefficient p value Coefficient p value
Univariate Index 3.484 < 0.001 4.244 < 0.001
Multivariate Age 0.043 < 0.001 0.039 0.002
GCS-Motor − 0.164 0.130 − 0.169 0.127
Pupillary response 0.457 0.067 0.474 0.068
ICP 0.071 0.005 0.061 0.019
CPP 0.034 0.128 0.035 0.128
Index 1.628 0.152 3.140 0.007
D Parameter ΔCPPopt: LPRx ΔCPPopt: PRx
Coefficient p value Coefficient p value
Univariate ΔCPPopt − 0.122 0.003 − 0.148 < 0.001
Multivariate Age 0.050 < 0.001 0.051 < 0.001
GCS-Motor − 0.166 0.124 − 0.190 0.086
Pupillary response 0.466 0.067 0.423 0.106
ICP 0.067 0.009 0.065 0.011
CPP 0.042 0.066 0.046 0.048
Index − 0.108 0.065 − 0.146 0.002
ΔCPPopt difference between cerebral perfusion pressure and calculated optimal cerebral perfusion pressure, GCS-Motor Glasgow Coma Scale motor component,
LPRx long pressure reactivity index, PRx pressure reactivity index
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analyzed outcome in a subgroup of patients whose CPP
deviated on average by at least ± 5 mmHg from their cal-
culated CPPoptLPRx (n = 32) and CPPoptPRx (n = 50,
Fig. 5a–d). Of 18 patients with a mean ΔCPPoptPRx > 5
mmHg (“hyperperfused” patients), only one patient died
(6%). In contrast, 15 of 32 patients with a mean
ΔCPPoptPRx < − 5 mmHg (“hypoperfused” patients) were
dead at the 6-month follow-up (47%). The mortality
rates differed significantly between those groups (χ2 =
7.24, p = 0.007). According to the calculated CPPoptLPRx,
a mean ΔCPPoptLPRx > 5 mmHg was present in 18 pa-
tients with the same mortality rate of 6%. However, only
14 patients were determined to be on average at least 5
mmHg below their CPPoptLPRx (ΔCPPoptLPRx < − 5
mmHg), and of those, 5 had died (35%). The mortality
rates when comparing “hypo- and hyperperfused” pa-
tients according to CPPoptLPRx missed statistical signifi-
cance (χ2 = 2.93, p = 0.087).
Eight of 32 patients (25%) with a mean ΔCPPoptPRx <
− 5 mmHg were severely disabled after 6 months. This
proportion was distinctively higher in patients with a
mean ΔCPPoptPRx > 5 mmHg with 10 of 18 patients
(56%), although the rates of severe disability between
those two patient groups did not reach statistical signifi-
cance (χ2 = 3.44, p = 0.064). Similar results were found
for the CPPoptLPRx: 3 of 14 patients (27%) with a mean
ΔCPPoptLPRx < − 5 mmHg and 10 of 18 patients (56%)
with a mean ΔCPPoptLPRx > 5 mmHg were severely dis-
abled 6 months after injury (χ2 = 2.52, p = 0.113). Again,
similar results were obtained in all statistical tests when
only patients without decompressive surgery were con-
sidered (data not shown).
Discussion
To individualize therapy is a promising concept for
possible reduction of mortality and unfavorable outcome
in patients with TBI. Regulating CPP according to
computed CPPopt recommendations derived from cere-
brovascular reactivity indices might hereby play an
important role. However, it remains unclear if high-
resolution data for PRx calculation is necessary to obtain
relevant CPPopt values or if low-resolution, minute-by-
minute signals for LPRx calculation might suffice. This
question is particularly important because using the
LPRx would make the CPPopt concept available to a
wider range of centers and thus patients. The first two
Fig. 3 AUCs for the prediction of mortality for different regression models. a LPRx and PRx. b IMPACT variables with the addition of LPRx and
PRx. c ΔCPPoptLPRx and ΔCPPoptPRx. d IMPACT variables with the addition of ΔCPPoptLPRx and ΔCPPoptPRx
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pilot studies examining the LPRx showed encouraging
results, stating that LPRx seemed to perform equally well
in outcome prediction and CPPopt calculation as the
PRx [17, 18]. However, the validity of those studies was
limited by relatively small patient numbers (18 and 29,
respectively). More recently, a larger (over 300 patients)
single-center follow-up study concluded the low-
resolution LPRx to be less precise compared to PRx in
outcome prediction which our results seem to confirm
[8]. The proposed weaker discriminative ability could be
further supported by our data especially when ICP and
CPP were also added to the IMPACT variables in a
multivariate model, where PRx but not LPRx remained a
significant predictor. The reason for this inferior per-
formance is likely that the LPRx only includes slower
drifts in ABP and ICP which provide less information on
the state of autoregulation, as opposed to the PRx which
also includes higher frequency wave components, likely
representing more outcome-relevant autoregulatory
responses.
However, even when performing to some extent worse
than the PRx in outcome prediction, the LPRx almost al-
ways showed significant results in our analyses as well
and the differences of AUCs between PRx and LPRx in
univariate regression to mortality were non-significant in
our current work (albeit in a smaller sample). This was
also true when comparing the discriminative value of
both indices day-by-day during the early post-injury time
course (first 6 days).
What is very important is that both indices signifi-
cantly improved the performance of a multivariable
model containing the IMPACT core variables and
remained independent predictors for mortality after TBI.
However, LPRx lost significance when also adjusting for
ICP and CPP. Nevertheless, when taken together, those
results seem to support the notion proposed by previous
studies [19, 22] that minute-by-minute averaged signals,
while performing to some extent weaker, might still
carry important outcome-related information and might
be sufficient for autoregulation monitoring via pressure
reactivity indices. Notably, both indices performed
considerably worse when predicting unfavorable out-
come compared to predicting mortality, which is also in
accordance with previous studies [10, 11]. A subgroup
analysis showed an especially strong association with
outcome for LPRx/PRx in patients with severe TBI,
making our results particularly applicable for such
patients.
Given the abovementioned findings, we sought to
evaluate the performance of a weighted, multi-window
Fig. 4 AUCs for the prediction of mortality and unfavorable outcome over the early post-traumatic time course. a LPRx and PRx in regard to
mortality. b LPRx and PRx in regard to unfavorable outcome. c ΔCPPoptLPRx and ΔCPPoptPRx in regard to mortality. d ΔCPPoptLPRx and
ΔCPPoptPRx in regard to unfavorable outcome. The only significant difference was observed at day 6 between LPRx and PRx (*p = 0.007)
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algorithm for assessing CPPopt that is based on the
LPRx instead of the PRx. Determination of CPPopt has
the potential to translate the PRx/LPRx concept into
clinical management by offering dynamic management
targets for CPP according to CPPopt. Ideally, patients
might then directly benefit from this individualized ther-
apy. The CPPopt concept built on PRx values has been
shown to be of prognostic value in numerous studies in
the sense that deviations of CPP from CPPopt were pre-
dictors of fatal outcome in TBI patients [12–15, 19, 23].
While the first automated CPPopt algorithm was based
on PRx/CPP values in a moving single-window of 4 h for
calculation [13], this method was extended to include
multiple windows for calculations by Depreitere et al.
[19], who used minute-by-minute monitoring data and
various low-resolution indices for their approach. They
could show that the resulting CPPopt was highly related
to outcome and was not inferior in outcome prediction
compared to the single-window CPPoptPRx which is
based on high-resolution data.
The multi-window concept developed by Depreitere
et al. was then adapted to high-resolution data, and thus
PRx, and extended with additional weighting and safety
criteria as well as more calculation windows in an algo-
rithm implemented in ICM+ by Liu et al. [14], and sub-
sequently modified further to make it suitable for
clinical, bedside application as part of the COGiTATE
trial [16]. In our study, we sought to evaluate how the
low-resolution LPRx, instead of the PRx, would perform
in this most recent CPPopt calculation method. Using
the CENTER-TBI high-resolution ICU cohort, we were
able to do this in direct reference to the PRx-based ap-
proach and in a multi-center dataset. Similar to the
LPRx itself, CPPoptLPRx performed slightly worse in out-
come prediction than its PRx counterpart but was still a
significant predictor for mortality in univariate and
multivariate analysis including the IMPACT variables.
Both ΔCPPoptLPRx and ΔCPPoptPRx were significant pre-
dictors of mortality, even when patients were adjusted
for other prognostic factors in multivariate analysis, and
their addition to the IMPACT core model could signifi-
cantly improve the goodness-of-fit. Addition of ΔCPPopt
displayed even higher AUCs for mortality than addition
of reactivity indices to the model. Interestingly, when
also including ICP and CPP in addition to the IMPACT
variables in the model, ΔCPPoptPRx remained significant
while ΔCPPoptLPRx failed to demonstrate significance in
the entire cohort. However, ΔCPPoptLPRx remained sig-
nificant in non-decompressed patients, indicating a po-
tential use in this patient group. All those results seem
to emphasize the importance that the deviation of CPP
from CPPopt might have in regard to clinical outcome.
Fig. 5 Bar graphs showing the proportion of fatal outcome (a, b) and severe disability (c, d) in patients with a mean deviation of at least 5
mmHg below or above their CPPoptLPRx or CPPoptPRx
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Further studies should examine the extension of the IM-
PACT core model with autoregulation monitoring indi-
ces, analogous to the already present IMPACT core +
CT model or IMPACT core + CT + laboratory markers
model.
When only patients with a relevant mean CPP/CPPopt
deviation were considered, the CPPoptPRx method de-
tected more patients overall and showed a closer relation
to mortality in patients with an average deviation in CPP
of at least 5 mmHg below the PRx-CPPopt. Even the
CPPoptLPRx showed a substantially higher mortality rate
in “hypoperfused” patients when compared to “hyperper-
fused” ones, although this difference between mortality
rates did not reach significance. Similar to Aries et al.
[13], we found a higher rate of severe disability in
“hyperperfused” patients compared to “hypoperfused”
ones. However, this association did not reach signifi-
cance in our study.
Concerning our results on CPPopt availability (yield of
the algorithm), it has to be mentioned that CPPoptPRx/
CPPoptLPRx could not be calculated in 8 patients, for
reason not related to a failure of the CPPopt algorithm.
In 5 patients, ICP was so high and CPP so low that the
autoregulation was completely and entirely lost, and the
concept of “optimal” CPP was therefore not applicable.
In further 3 patients, there was simply not enough data
available to perform the calculation. In all the remaining
patients, the fraction of time where CPPopt could be
determined was importantly very similar between
CPPoptLPRx and CPPoptPRx.
Interestingly, the exclusion of patients who underwent
decompressive surgery during their ICU stay did not
affect the results in most of our analyses (data not
shown), similar to previously published results in other
studies. A notable exception is that ΔCPPoptLPRx
remained a significant predictor for mortality in a multi-
variate model including ICP and CPP only in non-
decompressed patients while miss significance in the en-
tire cohort. This is despite the fact that the performance
of PRx and thus also LPRx, as the pressure reactivity
monitor, depends on reliable transmission of changes in
cerebral blood volume into intracranial pressure [24, 25],
and that is theoretically adversely affected by the decom-
pressive craniectomy. However, the exact timing of de-
compressive surgery could play an important role as
indices are averaged over the whole monitoring period
and future studies should be conducted to examine this
relationship closer.
Limitations
As the CENTER-TBI study was designed to be a prospect-
ive observational study, treatment strategies and protocols
in ICUs might considerably differ between participating
centers and might therefore be confounders. Importantly,
ICP and mean arterial pressure (MAP) signals were sub-
ject to manipulation by treating clinicians (e.g., actively
lowering ICP or MAP in selected patients) and might
therefore be also the result of therapeutic interventions.
Moreover, this study contains a heterogenous group of pa-
tients in terms of demographics, injury characteristics, and
comorbidities which might influence the results. Finally,
the considered variables such as the indices and differ-
ences between CPP and CPPopt were averaged over the
entire monitoring time per patient which could mean that
their variability and the presence of short periods with
very deviated values were not accounted for in our ana-
lysis. Regarding the temporal course of the discriminative
power of both indices, it is important to note that the
sample size considerably decreased over time which might
influence the results especially at later time points. While
this multi-center study can provide evidence for the rele-
vance of LPRx and CPPoptLPRx, a high-quality, prospective
study is needed to conclude whether the CPPoptLPRx con-
cept can be translated into clinical benefit in patients with
TBI.
Conclusions
Our findings indicate that the LPRx and multi-window
CPPoptLPRx do not reach the precision of the PRx and
CPPoptPRx in outcome prediction after TBI. However,
the LPRx is still significantly associated with outcome
and can produce outcome-relevant CPPopt values, most
reliably in non-decompressed patients. A prospective
trial is needed to assess if this association is strong
enough for a meaningful clinical translation. Should the
ongoing COGiTATE feasibility/safety trial and subse-
quent phase 3 trials be successful in proving the CPPopt
concept, it might be worthy to consider a respective trial
with the CPPoptLPRx to make the CPPopt concept avail-
able to a broader range of centers and patients.
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